• H.C. Wainwright sets a new price target of $185 for NASDAQ:BLTE, indicating a 20.4% potential upside.
• Belite Bio's experimental drug for a rare genetic eye disease meets its primary objective in a late-stage clinical trial.
• The company's stock price has shown significant volatility, with a 6.96% increase to $147.01 following the trial success.

Belite Bio, trading under the symbol NASDAQ:BLTE, is a biopharmaceutical company focused on developing treatments for rare genetic diseases. Recently, H.C. Wainwright set a new price target of $185 for BLTE, a 20.4% increase from its current trading price of $153.65. This adjustment reflects optimism in the company's potential growth and market performance.

The optimism surrounding BLTE is largely due to the successful results of its experimental drug for a rare genetic eye disease. The drug achieved its primary objective in a late-stage clinical trial, marking a significant milestone for Belite Bio. This success could lead to further advancements and regulatory approvals, enhancing the company's position in the market.

Currently, BLTE is priced at $147.01, having experienced a price change of $9.57, which is a 6.96% increase. The stock has shown volatility, with today's trading range between $130.06 and $159.71. Over the past year, BLTE has reached a high of $154.99 and a low of $49, indicating significant price fluctuations.

Belite Bio's market capitalization is approximately $5.13 billion, reflecting its substantial presence in the biopharmaceutical industry. The trading volume of 651,051 shares suggests active investor interest, likely driven by the recent positive trial results and the new price target set by H.C. Wainwright.